| Literature DB >> 33851745 |
M Laura Feltri1,2,3, Nadav I Weinstock1,2, Jacob Favret1,4, Narayan Dhimal1,2, Lawrence Wrabetz1,2,3, Daesung Shin1,4.
Abstract
Globoid cell leukodystrophy (GLD), also known as Krabbe disease, is a lysosomal storage disorder causing extensive demyelination in the central and peripheral nervous systems. GLD is caused by loss-of-function mutations in the lysosomal hydrolase, galactosylceramidase (GALC), which catabolizes the myelin sphingolipid galactosylceramide. The pathophysiology of GLD is complex and reflects the expression of GALC in a number of glial and neural cell types in both the central and peripheral nervous systems (CNS and PNS), as well as leukocytes and kidney in the periphery. Over the years, GLD has garnered a wide range of scientific and medical interests, especially as a model system to study gene therapy and novel preclinical therapeutic approaches to treat the spontaneous murine model for GLD. Here, we review recent findings in the field of Krabbe disease, with particular emphasis on novel aspects of GALC physiology, GLD pathophysiology, and therapeutic strategies.Entities:
Keywords: Krabbe disease; demyelination; leukodystrophy; neurodegeneration
Mesh:
Substances:
Year: 2021 PMID: 33851745 PMCID: PMC8502241 DOI: 10.1002/glia.24008
Source DB: PubMed Journal: Glia ISSN: 0894-1491 Impact factor: 7.452